NEW YORK, Oct. 15 – A US District Court has dismissed two claims filed by Affymetrix which asserted that Incyte had violated its “two-color” patent, Incyte said on Monday.

In a statement, Incyte said that the US District Court for the Northern District of California issued a summary judgment ruling dismissing claims that Incyte had violated ab patent designed to protect Affymetrix’s use of two-color fluorescent labels in microarray experiments. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.